Document Detail


Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.
MedLine Citation:
PMID:  22964235     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hemodialysis is the most common method used to remove waste and hazardous products of metabolism in patients suffering from renal failure. Hundreds of thousands of people with end-stage renal disease undergo hemodialysis treatment in the United States each year. Strikingly, the 5-year survival rate for all dialysis patients is only 35%. Most of the patients succumb to cardiovascular disease that is exacerbated by the chronic induction of inflammation caused by contact of the blood with the dialysis membrane. The complement system, a strong mediator of pro-inflammatory networks, is a key contributor to such biomaterial-induced inflammation. Though only evaluated in experimental ex vivo settings, specific targeting of complement activation during hemodialysis has uncovered valuable information that points toward the therapeutic use of complement inhibitors as a means to control the unwelcomed inflammatory responses and consequent pathologies in hemodialysis patients.
Authors:
Robert A DeAngelis; Edimara S Reis; Daniel Ricklin; John D Lambris
Related Documents :
24052155 - Estimation of tissue and serum lipocalin-2 in psoriasis vulgaris and its relation to me...
23522015 - (99m) tc-labelled human serum albumin cannot replace (125) i-labelled human serum album...
1928215 - Oxidative metabolism of circulating granulocytes in adult respiratory distress syndrome.
24929035 - Clinical presentation and diagnosis of toxoplasmic encephalitis in japan.
9290265 - Soluble tumor necrosis factor receptor in serum of patients with arthritis.
21857985 - Chronic myeloid leukemia patients in prolonged remission following interferon-α monoth...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Immunobiology     Volume:  217     ISSN:  1878-3279     ISO Abbreviation:  Immunobiology     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-09-11     Completed Date:  2013-03-14     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  8002742     Medline TA:  Immunobiology     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1097-105     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier GmbH. All rights reserved.
Affiliation:
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biocompatible Materials
Cardiovascular Diseases / etiology,  immunology
Complement Activation*
Complement Inactivator Proteins*
Complement System Proteins / immunology,  metabolism*
Humans
Inflammation / etiology,  immunology,  pathology,  prevention & control*
Kidney Failure, Chronic / blood,  therapy
Molecular Targeted Therapy
Renal Dialysis / adverse effects*
Grant Support
ID/Acronym/Agency:
AI068730/AI/NIAID NIH HHS; AI30040/AI/NIAID NIH HHS; GM097747/GM/NIGMS NIH HHS; P01 AI068730/AI/NIAID NIH HHS; R01 AI030040/AI/NIAID NIH HHS; R01 EY020633/EY/NEI NIH HHS; R01 GM097747/GM/NIGMS NIH HHS; Y020633//PHS HHS
Chemical
Reg. No./Substance:
0/Biocompatible Materials; 0/Complement Inactivator Proteins; 9007-36-7/Complement System Proteins
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interactions of the complement system with molecules of extracellular matrix: Relevance for joint di...
Next Document:  The tick-over theory revisited: Is C3 a contact-activated protein?